following a full submission assessed under the end of life and ultra-orphan process:
nivolumab (Opdivo®) is accepted for use within NHS Scotland.
Indication under review: the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
In an open-label, single-arm study, a clinically meaningful objective response rate was achieved in patients with relapsed or refractory cHL treated with nivolumab.
SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of nivolumab and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice349KB (PDF)
- Medicine name:
- nivolumab (Opdivo)
- SMC ID:
- For the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Date advice published:
- 10 July 2017